WHAT MATTERS MOST? AN EXPLORATION OF DECISION CRITERIA CONSIDERED BY PATIENTS WITH GEP-NET AND PHYSICIANS USING HOLISTIC MULTI-CRITERIA DECISION ANALYSIS
Author(s)
Goetghebeur MM1, Samaha D2, O'Neil B2, Khoury H2, Bennetts L2, Lavoie L2, Wagner M2, Badgley D2, Gabriel S3, Berthon A4, Dolan J5, Kulke M6
1LASER Analytica and School of Public Health, University of Montreal, Montreal, QC, Canada, 2LASER Analytica, Montreal, QC, Canada, 3IPSEN Pharma, Boulogne-Billancourt, France, 4IPSEN, Boulogne-Billancourt, France, 5University of Rochester, Rochester, NY, USA, 6Dana-Farber Cancer Institute, Boston, MA, USA
OBJECTIVES: Patient-centered care implies identifying what matters most to patients and physicians through shared decisionmaking on disease management. EVIDEM provides a generic holistic MCDA platform to explore decision criteria and trade-offs. The study aimed to develop a comprehensive decision framework and identify preferences of patients and physicians in the management of unresectable, well- or moderately differentiated non-functioning GEP-NET. METHODS: A decision support framework was designed based on EVIDEM structure, literature review and insights from a Chatham-house panel of US physicians and patients, representative of different management approaches for GEP-NET. During a second extended panel session (5 patients, 6 physicians), participants provided criteria weights using Hierarchical Point Allocation and Direct Rating Scale (DRS, sensitivity analyses). Insights were collected in writing and through discussions. RESULTS: The decision support framework included 6 domains pertaining to Outcomes of the intervention (Effectiveness, Patient-Reported Outcomes, autonomy, dignity &convenience, Safety); Type of benefit; Need (Disease severity; Unmet needs; Population size); Costs & constraints (Intervention; Medical and Non-medical [to patients or the healthcare system]); Knowledge (Quality of evidence, Expert consensus) and Feasibility (System capacity). Of the 30 criteria and subcriteria, 26 were considered by more than 90% of participants. Criteria weights were widely distributed reflecting variability in individual perspectives on what matters most. At the group level, highest weights were attributed to Effectiveness (0.18 ± SD 0.12 on a total of 1) and Disease severity (0 .12 ± 0.08), followed by Safety (0.10 ± 0.09), Type of therapeutic benefit (0.10 ± 0.08) and Quality of evidence (0.09 ± 0.06). Most important Effectiveness subcriteria were Overall survival (33% of effectiveness criteria), followed by Progression-free survival (30%). DRS showed similar overall results. CONCLUSIONS: Many aspects are considered by patients and physicians in their decisionmaking processes. Holistic MCDA reveals and structures the complexity and variability of what matters most to patients.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PRM166
Topic
Methodological & Statistical Research
Topic Subcategory
PRO & Related Methods
Disease
Oncology